10-Q: Nuo Therapeutics Boosts Revenue with Smith & Nephew Deal, Raises Capital Amidst Going Concern Doubts

Nuo Therapeutics reported significant revenue growth driven by a new distribution agreement with Smith & Nephew and an interim sales agency, while also completing a private placement to address liquidity concerns and ongoing losses.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 92% to $700,202, including $75,000 in license revenue from the Smith & Nephew distribution agreement.
• Product sales for the three months ended June 30, 2025, grew to $625,202 from $364,773 in the prior year period.
• Net loss for the three months ended June 30, 2025, increased to $649,689 from $540,091 in the same period last year.
• For the six months ended June 30, 2025, total revenue nearly doubled to $1,184,583, compared to $599,350 in the prior year.
• Net loss for the six months ended June 30, 2025, was $1,395,817, an increase from $1,248,872 in the prior year period.
• Cash provided by operating activities significantly improved to $264,191 for the six months ended June 30, 2025, compared to cash used of $1,253,616 in the prior year, primarily due to a $1.5 million upfront distribution fee from Smith & Nephew.
• The company completed a private placement on July 30, 2025, raising $791,418 by selling 527,612 shares of common stock at $1.50 per share.
• An accumulated deficit of approximately $33.7 million and a stockholders' deficit of $824,561 as of June 30, 2025, raise substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: While Nuo Therapeutics achieved significant revenue growth and secured a strategic distribution agreement with Smith & Nephew, the company continues to incur substantial net losses and has an accumulated deficit, leading management to express 'substantial doubt' about its ability to continue as a going concern. The recent capital raise provides some liquidity, but the underlying financial health remains precarious, necessitating further external financing and posing significant dilution risks.

Positives

• Total revenue for the three months ended June 30, 2025, increased by 92% to $700,202, driven by product sales growth and a new license revenue stream.
• Product sales for the three months ended June 30, 2025, increased by $260,429 to $625,202 compared to the same period in 2024.
• The company received a $1.5 million upfront distribution fee from Smith & Nephew, significantly improving cash flow from operations to $264,191 for the six months ended June 30, 2025, compared to a cash outflow of $1,253,616 in the prior year.
• A new interim sales agency arrangement with Smith & Nephew allows S+N to promote and sell NUO-branded products to certain S+N customers, potentially expanding market reach.
• The Aurix System became economically viable in physician office care settings (POS 11) effective January 1, 2025, with a national average payment of $890, expanding market opportunity.
• The company has established contractual relationships with over 200 third-party entity and individual representatives, indicating a growing sales network.
• A shelf registration statement on Form S-3, declared effective May 12, 2025, provides access to up to $15 million in potential future equity financing.
• The recent private placement raised $791,418 for working capital, providing immediate liquidity.

Negatives

• The company incurred a net loss of $649,689 for the three months ended June 30, 2025, an increase from $540,091 in the prior year period.
• The net loss for the six months ended June 30, 2025, was $1,395,817, an increase from $1,248,872 in the prior year period.
• An accumulated deficit of approximately $33.7 million as of June 30, 2025, and a stockholders' deficit of $824,561 indicate a challenging financial position.
• Management believes that current resources and projected revenue are insufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Operating expenses increased significantly, with selling, general, and administrative expenses rising by $351,454 to $1,192,874 for the three months ended June 30, 2025, primarily due to increased professional fees and third-party commission expenses.
• Future equity financing may cause further substantial dilution to stockholders, and debt financing may impose onerous financial covenants.
• Material weaknesses in internal control over financial reporting persist due to a lack of sufficient accounting and financial reporting resources.

Risks

• Limited revenue base and sources of working capital.
• Limited operating experience.
• Ability to continue as a going concern.
• Dilutive impact of raising additional equity or debt.
• Ability to timely and accurately report financial results and prevent fraud if effective disclosure and internal controls are not maintained.
• Acceptance of the Aurix product by the medical community and patients.
• Ability to obtain adequate reimbursement from third-party payors.
• Ability to contract with healthcare providers.
• Reliance on several single-source suppliers, including Pfizer for bovine thrombin, and the ability to source raw materials at affordable costs.
• Ability to protect intellectual property.
• Compliance with governmental regulations.
• Ability to successfully sell and market the Aurix System.
• Ability to perform under and realize sales and related benefits from the distribution agreement with Smith & Nephew, as well as S+N's ability to market and sell its private label Aurix product.
• The fees, minimum purchase commitments, and expenses and costs associated with the distribution agreement with Smith & Nephew.
• The impact of and ability to undertake any license of the Aurix product, or receive and negotiate a business combination offer, due to the binding notification and negotiation rights provided to Smith & Nephew.
• Ability to successfully pursue strategic collaborations to help develop, support, or commercialize current and future products.

Future Outlook

The company anticipates modest sales under the Smith & Nephew Distribution Agreement during the next 12 months as S+N establishes its commercial sales. It expects revenues to continue growing in the future, driven by an expanding customer base and increased awareness of the Aurix product and Medicare NCD. The company will continue to assess the need for hiring additional internal accounting and third-party financial reporting resources to remediate material weaknesses in internal controls. It also plans to continue financing operations with external capital for the foreseeable future, including potentially utilizing its effective shelf registration statement for up to $15 million in equity offerings.

Management Comments

• "We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products are insufficient to support our operations for the next 12 months from the date these financial statements are issued."
• "We believe that Smith+Nephew will need time to establish and begin commercial sales of its Private Label product."
• "We anticipate modest sales under the Distribution Agreement during the next 12 months."
• "We expect revenues will continue growing in the future."
• "The number of sales agent representatives may continue to expand modestly in the months ahead, but the current focus is establishing commercial customer relationships with wound care providers in primarily hospital outpatient wound care clinics and ensuring that the reimbursement mechanisms are appropriately administered by the local Medicare Administrative Contractors in support of the April 2021 NCD."
• "Management believes that the consolidated financial statements and related financial information included in this Quarterly Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with GAAP."

Industry Context

Nuo Therapeutics operates in the advanced wound care market, estimated at approximately $10.8 billion globally in 2021 and $4.15 billion in North America in 2020. The market is driven by an aging population and increasing prevalence of diabetes, leading to a growing patient population at risk of chronic, non-healing wounds. The company's Aurix System, a platelet-rich plasma (PRP) therapy, competes within this segment, benefiting from a favorable 2021 Medicare National Coverage Determination for diabetic wounds and recent economic viability in physician office settings. The strategic distribution agreement with Smith & Nephew, a global medical technology company, positions Nuo to potentially expand its market reach and adoption within the broader wound care industry, leveraging S+N's established customer base.

Corporate Governance

Legal Proceedings

• No claims or actions pending against the company, the ultimate disposition of which could have a material adverse effect on results of operations, financial condition, or cash flows.

Related Party Transactions

• Scott M. Pittman, a member of the Board of Directors, invested $5,919 in the July 30, 2025 private placement.
• Charles E. Sheedy, a principal stockholder, invested $200,000 in the July 30, 2025 private placement.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing and future capital raises, as well as the risk of potential loss of investment due to the company's going concern doubts and accumulated deficit.
• Employees: The company furloughed employees in 2019 and restarted operations in 2021, indicating past instability; current stock-based compensation plans are in place.
• Customers (Healthcare Providers & Patients): Benefit from increased access to the Aurix System through the new distribution agreement with Smith & Nephew and improved reimbursement viability in physician offices.
• Suppliers: The company's reliance on single-source suppliers, such as Pfizer for bovine thrombin, poses a risk of supply interruption or increased costs.
• Creditors: May face increased risk due to the company's accumulated deficit and stated inability to support operations for the next 12 months without additional funding.

Next Steps

• Smith & Nephew to establish and begin commercial sales of its Private Label product.
• Nuo Therapeutics to continue engaging and establishing relationships with providers treating chronic non-healing wounds.
• Nuo Therapeutics to continue establishing a variety of distributor and sales agent arrangements throughout the United States and internationally.
• Nuo Therapeutics to establish commercial customer relationships with wound care providers in primarily hospital outpatient wound care clinics.
• Nuo Therapeutics to ensure reimbursement mechanisms are appropriately administered by local Medicare Administrative Contractors.
• Nuo Therapeutics to continue assessing the need for hiring additional internal accounting and third-party financial reporting resources to remediate material weaknesses in internal controls.
• Nuo Therapeutics to implement measures designed to improve internal control over financial reporting.
• Nuo Therapeutics to continue financing operations with external capital for the foreseeable future.

Key Dates

Recommendation

While Nuo Therapeutics has demonstrated strong revenue growth and secured a significant distribution agreement with Smith & Nephew, indicating positive commercial momentum for its Aurix product, the company's persistent net losses and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The recent capital raise provides a temporary liquidity boost, but the need for continuous external financing and the associated dilution risk for existing shareholders are significant concerns. The strategic partnership and market expansion opportunities are positive, but the fundamental financial instability and internal control weaknesses warrant a cautious 'hold' recommendation. Investors should monitor the company's progress in achieving profitability, securing further financing, and remediating internal control issues before considering a stronger position.

Keywords

Nuo Therapeutics, Aurix System, Smith & Nephew, Distribution Agreement, SEC Filing, 10-Q, Medical Device, Wound Care, Platelet Rich Plasma, PRP, Going Concern, Capital Raise, Financial Results, Healthcare, Biologics, Diabetic Ulcers, Reimbursement, FDA, CMS, Private Placement, Stockholders' Deficit